

INSTITUT FÜR PROPHYLAXE & EPIDEMIOLOGIE DER KREISLAUFKRANKHEITEN (IPEK)

DIREKTOR: UNIV.-PROF. DR. CHRISTIAN WEBER

ANZAHL DER HAUSHALTFINANZIERTEN WISSENSCHAFTLICHE MITARBEITER: 23

ANZAHL DER HAUSHALTFINANZIERTEN NICHT-WISSENSCHAFTLICHE MITARBEITER: 19

ANZAHL ALLER DRITTMITTELFINANZIERTEN MITARBEITER: 75

DRITTMITTELAUSGABEN (IN €):

	Anzahl Projekte	Ausgaben 2020
DFG	35	3.952.012
BMBF, StMWFK	20	1.544.473
EU	6	1.169.598
Stiftungen (Humboldt, Fondation Leducq, etc.)	9	250.576
Summe begutachtete externe Drittmittel	70	6.916.659

	Anzahl Projekte	Ausgaben 2020
FöFoLe	1	54.408
Promotionsstipendien	2	4.102
Summe interne Drittmittel		58.510

Gesamtsumme verausgabte Drittmittel		6.975.169
--	--	------------------

PUBLIKATIONEN:

	Anzahl	ungewichteter IF
im WoS gelistete Originalarbeiten	39	520,6
im WoS gelistete Reviews, Editorials	39	325,2
Gesamtsumme	78	845,8

FORSCHUNGSSCHWERPUNKTE

- Chemokine und Chemokinrezeptoren bei entzündlicher und atherogener Leukozytenrekrutierung
- Versatile Regulation der Atherosklerose durch microRNAs
- Funktion der Neutrophilen und Ihrer Sekretion in frühen Stadien der Atherosklerose
- Rolle von Chemokinen und Chemokin-ähnliche Funktionen von MIF in der Atherosklerose und Restenose
- Struktur und Funktion der Heterooligomerisierung und Proteoglykanbindung von Chemokinen („Interaktom“)
- Signaltransduktion der Integrinregulation in Leukozyten und der endothelialen Aktivierung durch Zytokine
- Junktionale Adhäsionsmoleküle in der transendothelialen Diapedese und der vaskulären Entzündungsreaktion
- Chemokine und ihre Rezeptoren in der myokardialen Ischämie-Reperfusion und bei Myokardinfarkt
- Rolle von Leukozytensubpopulationen (Monozyten, T Zellen, dendritische Zellen, Mastzellen) in der Atherosklerose
- Regulation der Homöostase und Rekrutierung vaskulärer Vorläuferzellen in der Atherosklerose und nach Infarkt
- Physiologie und Pathophysiologie endothelialer Vorläuferzellen in der Endothelregeneration und Risikobestimmung
- Statine zur Prävention der Endotheldysfunktion und miniaturisierte, eluierende Formgedächtnis- und Polymer-Stents
- Intravitalmikroskopie, 2-Photonmikroskopie und Mechanismen der Plaquestabilisierung
- Transmembranäre Chemokine und proteolytische Spaltung durch ADAM Metalloproteasen
- Rolle des Endocannabinoidsystems in der Atherosklerose und Ischämie/Reperfusion
- Mechanismen von ApoE bei Entzündung, Alzheimer und Atherosklerose
- Neuroimmune Grenzflächen, Innervation und Autoimmunität in der Atherosklerose

PUBLIKATIONEN

Originalarbeiten, Reviews, Editorials - gelistet im Web of Science (WoS)

1. Adrover JM, Aroca-Crevillen A, Crainiciuc G, Ostos F, Rojas-Vega Y, Rubio-Ponce A, Cilloniz C, Bonzon-Kulichenko E, Calvo E, Rico D, Moro MA, Weber C, Lizasoain I, Torres A, Ruiz-Cabello J, Vazquez J, Hidalgo A. Programmed 'disarming' of the neutrophil proteome reduces the magnitude of inflammation. *Nat Immunol.* 2020;21:135-144. (IF: 20,479)
2. Aroca-Crevillen A, Adrover JM, Hidalgo A. Circadian Features of Neutrophil Biology. *Front Immunol.* 2020;11:576. (IF: 5,016)
3. Asare Y, Campbell-James TA, Bokov Y, Yu LL, Prestel M, El Bounkari O, Roth S, Megens RT, Straub T, Thomas K, Yan G, Schneider M, Ziesch N, Tiedt S, Silvestre-Roig C, Braster Q, Huang Y, Schneider M, Malik R, Haffner C, Liesz A, Soehnlein O, Bernhagen J, Dichgans M. Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability. *Circulation research.* 2020;127:811-823. (IF: 14,467)
4. Baardman J, Lutgens E. Regulatory T Cell Metabolism in Atherosclerosis. *Metabolites.* 2020;10 :279. (IF : 4,097)
5. Baardman J, Verberk SGS, van der Velden S, Gijbels MJJ, van Roomen C, Sluimer JC, Broos JY, Griffith GR, Prange KHM, van Weeghel M, Lakbir S, Molenaar D, Meinster E, Neele AE, Kooij G, de Vries HE, Lutgens E, Wellen KE, de Winther MPJ, Van den Bossche J. Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques. *Nat Commun.* 2020;11:6296. (IF: 12,121)
6. Baehr A, Hinkel R, Kupatt C. Statins Make a Difference in Acute Myocardial Infarction: A Revival. *J Am Coll Cardiol.* 2020 Mar 31;75(12):1403-1405. doi: 10.1016/j.jacc.2020.02.008 (IF: 20,589)
7. Baehr A, Umansky KB, Bassat E, Jurisch V, Klett K, Bozoglu T, Hornaschewitz N, Solyanik O, Kain D, Ferraro B, Cohen-Rabbi R, Krane M, Cyran C, Soehnlein O, Laugwitz KL, Hinkel R, Kupatt C, Tzahor E. Agrin Promotes Coordinated Therapeutic Processes Leading to Improved Cardiac Repair in Pigs. *Circulation.* 2020;142:868-881. (IF: 2,540)
8. Ballesteros I, Rubio-Ponce A, Genua M, Lusito E, Kwok I, Fernandez-Calvo G, Khoyratty TE, van Grinsven E, Gonzalez-Hernandez S, Nicolas-Avila JA, Vicanolo T, Maccataio A, Benguria A, Li JL, Adrover JM, Aroca-Crevillen A, Quintana JA, Martin-Salamanca S, Mayo F, Ascher S, Barbiera G, Soehnlein O, Gunzer M, Ginhoux F, Sanchez-Cabo F, Nistal-Villan E, Schulz C, Dopazo A, Reinhardt C, Udalova IA, Ng LG, Ostuni R, Hidalgo A. Co-option of Neutrophil Fates by Tissue Environments. *Cell.* 2020;183:1282-1297.e1218. (IF: 38,637)
9. Bartelt A, Weber C. Mitochondrial Ejection for Cardiac Protection: The Macrophage Connection. *Cell Metab.* 2020;32:512-513. (IF: 21,567)
10. Bartelt A, Widenmaier SB. Proteostasis in thermogenesis and obesity. *Biol Chem.* 2020;401:1019-1030. (IF: 3,270)
11. Bosch L, de Haan JJ, Seijkens TTP, van Tiel CM, Brans MAD, Pasterkamp G, Lutgens E, de Jager SCA. The therapeutic potential of targeting CD40-TRAF6 pathway in cardiovascular Diseases. *Int J Cardiol.* 2020;300:220. (IF: 3,229)
12. Butt E, Stempfle K, Lister L, Wolf F, Kraft M, Herrmann AB, Viciano CP, Weber C, Hochhaus A, Ernst T, Hoffmann C, Zerneck A, Frietsch JJ. Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia. *Cells.* 2020;9. (IF: 38,637)
13. Chen HJ, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. *J Exp Med.* 2020;217. (IF: 11,743)
14. Cribbs AP, Terlecki-Zaniewicz S, Philpott M, Baardman J, Ahern D, Lindow M, Obad S, Oerum H, Sampey B, Mander PK, Penn H, Wordsworth P, Bowness P, de Winther M, Prinjha RK, Feldmann M, Oppermann U. Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism. *Proc Natl Acad Sci U S A.* 2020;117:6056-6066. (IF: 9,412)
15. d'Alessandro E, Becker C, Bergmeier W, Bode C, Bourne JH, Brown H, Buller HR, Ten Cate-Hoek AJ, Ten Cate V, van Cauteren YJM, Cheung YFH, Cleuren A, Coenen D, Crijns H, de Simone I, Dolleman SC, Klein CE, Fernandez DI, Granneman L, van THA, Henke P, Henskens YMC, Huang J, Jennings LK, Jooss N, Karel M, van den Kerkhof D, Klok FA, Kremers B, Lammle B, Leader A, Lundstrom A, Mackman N, Mannucci PM, Maqsood Z, van der Meijden PEJ, van Moorsel M, Moran LA, Morser J, van Mourik M, Navarro S, Neagoe RAI, Olie RH, van Paridon P, Posma J, Provenzale I, Reitsma PH, Scaf B, Schurgers L, Seelig J, Siegbahn A, Siegerink B, Soehnlein O, Soriano EM, Sowa MA, Spronk HMH, Storey RF, Tantiwong C, Veninga A, Wang X, Watson SP, Weitz J, Zeerleder SS, Ten Cate H, Scientific Reviewer Committee. Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. *Thromb Haemost.* 2020;120:538-564. (IF: 4,358)
16. Daub S, Lutgens E, Munzel T, Daiber A. CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-The Pros and Cons for Cardioprotection. *Int J Mol Sci.* 2020;21 (IF: 4,556).
17. Denisov SS, Heinzmann ACA, Vajen T, Vries MHM, Megens RTA, Suylen D, Koenen RR, Post MJ, Ippel JH, Hackeng TM, Dijkgraaf I. Tick Saliva Protein Evasin-3 Allows for Visualization of Inflammation in Arteries through Interactions with CXC-Type Chemokines Deposited on Activated Endothelium. *Bioconjug Chem.* 2020;31:948-955 (IF: 4,031)
18. Depuydt MA, Prange KH, Slenders L, Ord T, Elbersen D, Boltjes A, de Jager SC, Asselbergs FW, de Borst GJ, Aavik E, Lonnberg T, Lutgens E, Glass CK, den Ruijter HM, Kaikkonen MU, Bot I, Slutter B, van der Laan SW, Yla-Herttuala S, Mokry M, Kuiper J, de Winther MP, Pasterkamp G. Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics. *Circ Res.* 2020;127:1437-1455. (IF: 14,467)
19. Doring Y, Jansen Y, Cimen I, Aslani M, Gencer S, Peters LJ, Duchene J, Weber C, van der Vorst EV. B-Cell Specific CXCR4 Protects Against Atherosclerosis Development and Increases Plasma IgM Levels. *Circ Res.* 2020;126:787-788. (IF: 14,467)
20. Doring Y, Libby P, Soehnlein O. Neutrophil Extracellular Traps Participate in Cardiovascular Diseases: Recent Experimental and Clinical Insights. *Circ Res.* 2020;126:1228-1241. (IF: 14,467)
21. Doring Y, Noels H, van der Vorst E, Weber C. Seeing is repairing: how imaging-based timely interference with CXCR4 could improve repair after myocardial infarction. *Eur Heart J.* 2020;41:3576-3578. (IF: 22,673)
22. Dweck MR, Maurovich-Horvat P, Leiner T, Cosyns B, Fayad ZA, Gijzen FJH, Van der Heiden K, Kooi ME, Maehara A, Muller JE, Newby DE, Narula J, Pontone G, Regar E, Serruys PW, van der Steen AFW, Stone PH, Waltenberger JL, Yuan C, Evans PC, Lutgens E, Wentzel JJ, Back M. Contemporary rationale for non-invasive imaging of adverse coronary plaque features to identify the vulnerable patient: a Position Paper from the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging.* 2020;21:1177-1183. (IF: 4,841)
23. Eckardt V, Miller MC, Blanchet X, Duan R, Leberzammer J, Duchene J, Soehnlein O, Megens

- RT, Ludwig AK, Dregni A, Faussner A, Wichapong K, Ippel H, Dijkgraaf I, Kaltner H, Doring Y, Bidzhekov K, Hackeng TM, Weber C, Gabius HJ, von Hundelshausen P, Mayo KH. Chemokines and galectins form heterodimers to modulate inflammation. *EMBO Rep.* 2020:e47852. (IF: 7,497)
24. Evans PC, Ed Rainger G, Mason JC, Guzik TJ, Osto E, Stamataki Z, Neil D, Hofer IE, Fragiadaki M, Waltenberger J, Weber C, Bochaton-Piallat ML, Back M. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. *Cardiovasc Res.* 2020;116:2177-2184. (IF: 8,168)
 25. Ferdinandy P, Koller A, Weber C, Waltenberger J. Postponement of Frontiers in Cardiovascular Biomedicine (FCVB) 2020 due to COVID-19: a look forward to 2021. *Cardiovascular research.* 2020;116:e78-e81. (IF: 8,168)
 26. Franke K, Pillai SY, Hoogenboezem M, Gijbels MJJ, Matlung HL, Geissler J, Olzman H, Pottgens C, van Gorp PJ, Ozsvar-Kozma M, Saito Y, Matozaki T, Kuipers TW, Hendriks RW, Kraal G, Binder CJ, de Winther MPJ, van den Berg TK. SIRPalpha on Mouse B1 Cells Restricts Lymphoid Tissue Migration and Natural Antibody Production. *Front Immunol.* 2020;11:570963 (IF: 5,016).
 27. Gencer S, Lacy M, Atzler D, van der Vorst EPC, Doring Y, Weber C. Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19. *Thromb Haemost.* 2020;120:1629-1641. (IF: 4,385)
 28. Gomez I, Ward B, Souilhol C, Recarti C, Ariaans M, Johnston J, Burnett A, Mahmoud M, Luong LA, West L, Long M, Parry S, Woods R, Hulston C, Benedikter B, Niespolo C, Bazaz R, Francis S, Kiss-Toth E, van Zandvoort M, Schober A, Hellewell P, Evans PC, Ridger V. Neutrophil microvesicles drive atherosclerosis by delivering miR-155 to atheroprone endothelium. *Nat Commun.* 2020;11:214. (IF: 12,121)
 29. Greiffo FR, Viteri-Alvarez V, Frankenberger M, Diel D, Ortega-Gomez A, Lee JS, Hilgendorff A, Behr J, Soehnlein O, Eickelberg O, Fernandez IE. CX3CR1-fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. *Eur Respir J.* 2020;55. (IF: 12,339)
 30. Groeneweg L, Hidalgo A, N AG. Emerging roles of infiltrating granulocytes and monocytes in homeostasis. *Cell Mol Life Sci.* 2020;77:3823-3830. (IF: 6,496)
 31. Hamid SM, Citir M, Terzi EM, Cimen I, Yildirim Z, Dogan AE, Kocaturk B, Onat UI, Ardit M, Weber C, Traynor-Kaplan A, Schultz C, Erbay E. Inositol-requiring enzyme-1 regulates phosphoinositide signaling lipids and macrophage growth. *EMBO Rep.* 2020:e51462. (IF: 7,497)
 32. Hinkel R, Ramanujam D, Kaczmarek V, Howe A, Klett K, Beck C, Dueck A, Thum T, Laugwitz KL, Maegdefessel L, Weber C, Kupatt C, Engelhardt S. AntimiR-21 Prevents Myocardial Dysfunction in a Pig Model of Ischemia/Reperfusion Injury. *J Am Coll Cardiol.* 2020;75:1788-1800. (IF: 20,589)
 33. Karshovska E, Wei Y, Subramanian P, Mohibullah R, Geissler C, Baatsch I, Popal A, Corbalan Campos J, Exner N, Schober A. HIF-1alpha (Hypoxia-Inducible Factor-1alpha) Promotes Macrophage Necroptosis by Regulating miR-210 and miR-383. *Arterioscler Thromb Vasc Biol.* 2020:ATVBAHA119313290. (IF: 6,604)
 34. Kessler T, Schunkert H, von Hundelshausen P. Novel Approaches to Fine-Tune Therapeutic Targeting of Platelets in Atherosclerosis: A Critical Appraisal. *Thromb Haemost.* Epub 2020. (IF: 4,358)
 35. Kiouptsi K, Pontarollo G, Todorov H, Braun J, Jackel S, Koeck T, Bayer F, Karwot C, Karpi A, Gerber S, Jansen Y, Wild P, Ruf W, Daiber A, Van Der Vorst E, Weber C, Doring Y, Reinhardt C. Germ-free housing conditions do not affect aortic root and aortic arch lesion size of late atherosclerotic low-density lipoprotein receptor-deficient mice. *Gut Microbes.* 2020:1-15. (IF: 7,740)
 36. Kontos C, El Bounkari O, Krammer C, Sinitski D, Hille K, Zan C, Yan G, Wang S, Gao Y, Brandhofer M, Megens RTA, Hoffmann A, Pauli J, Asare Y, Gerra S, Bourilhon P, Leng L, Eckstein HH, Kempf WE, Pelisek J, Gokce O, Maegdefessel L, Bucala R, Dichgans M, Weber C, Kapurniotu A, Bernhagen J. Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. *Nat Commun.* 2020;11:5981. (IF: 12,121)
 37. Kuznetsova T, Prange KHM, Glass CK, de Winther MPJ. Transcriptional and epigenetic regulation of macrophages in atherosclerosis. *Nat Rev Cardiol.* 2020;17:216-228. (IF: 20,260)
 38. Lip GYH, Rigby A, Weber C. A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis! *Thromb Haemost.* 2020;120:1-4. (IF: 4,358)
 39. Lu HS, Schmidt AM, Hegele RA, Mackman N, Rader DJ, Weber C, Daugherty A. Annual Report on Sex in Preclinical Studies: Arteriosclerosis, Thrombosis, and Vascular Biology Publications in 2018. *Arteriosclerosis, thrombosis, and vascular biology.* 2020;40:e1-e9. (IF: 6,604)
 40. Lutgens E. rs1883832: a CD40 single-nucleotide polymorphism for predicting coronary heart disease in humans. *Cardiovascular research.* 2020;116:1095-1096. (IF: 8,168)
 41. Lutgens E, Seijkens TTP. Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease. *J Immunother Cancer.* 2020;8. (IF: 3,121)
 42. Marquez AB, Nazir S, van der Vorst EPC. High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression? *Biomedicines.* 2020;8:549. (IF: 4,717)
 43. Nazir S, Jankowski V, Bender G, Zewinger S, Rye KA, van der Vorst EPC. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration! *Adv Drug Deliv Rev.* 2020;159:94-119. (IF: 13,300)
 44. Ortega-Gomez A, Soehnlein O. Lack of Proteinase 3 Stabilizes Advanced Atherosclerotic Lesions. *Thrombosis and haemostasis.* 2020;120:994-997. (IF: 4,385)
 45. Peters LJJ, Biessen EAL, Hohl M, Weber C, van der Vorst EPC, Santovito D. Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease. *Front Physiol.* 2020;11:793. (IF: 3,367)
 46. Peters LJJ, Floege J, Biessen EAL, Jankowski J, van der Vorst EPC. MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application. *Int J Mol Sci.* 2020;21. (IF: 4,183)
 47. Poels K, Schnitzler JG, Waissi F, Levels JHM, Stroes ESG, Daemen M, Lutgens E, Pennekamp AM, De Kleijn DPV, Seijkens TTP, Kroon J. Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. *Front Cell Dev Biol.* 2020;8:581641. (IF: 5,186)
 48. Poels K, van Lent MMT, Boutros C, Tissot H, Roy S, Meerwaldt AE, Toner YCA, Reiche M; Kusters P, Malinova T, Huveneers S, Kaufman A, Mani V, Fayad Z, de Winther MMPJ, Marabelle A, Mulder WJM, Robert C, Seijkens T, Lutgens E. Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. *J Am Coll Cardiol CardioOnc.* 2020 Nov, 2 (4) 599-610 (IF: 20,589)
 49. Poels K, van Leent MMT, Reiche ME, Kusters PJH, Huveneers S, de Winther MPJ, Mulder WJM, Lutgens E, Seijkens TTP. Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice. *Cells.* 2020;9. (IF: 38,637)
 50. Poels K, Vos WG, Lutgens E, Seijkens TTP. E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease. *Front Cardiovasc Med.* 2020;7:106. (IF: 0,659)
 51. Priem B, van Leent MMT, Teunissen AJP, Sofias AM, Mourits VP, Willemsen L, Klein ED, Oosterwijk RS, Meerwaldt AE, Munitz J, Prevot G, Vera Verschuur A,

- Nauta SA, van Leeuwen EM, Fisher EL, de Jong KAM, Zhao Y, Toner YC, Soultanidis G, Calcagno C, Bomans PHH, Friedrich H, Sommerdijk N, Reiner T, Duivenvoorden R, Zupancic E, Di Martino JS, Kluza E, Rashidian M, Ploegh HL, Dijkhuizen RM, Hak S, Perez-Medina C, Bravo-Cordero JJ, de Winther MPJ, Joosten LAB, van Elsas A, Fayad ZA, Rialdi A, Torre D, Guccione E, Ochando J, Netea MG, Griffioen AW, Mulder WJM. Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition. *Cell*. 2020;183:786-801 e719. (IF: 38,637)
52. Puhl SL. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia. *Biochim Biophys Acta Mol Cell Res*. 2020;1867:118462. (IF: 20,507)
53. Remie CME, Roumans KHM, Moonen MPB, Connell NJ, Havekes B, Mevenkamp J, Lindeboom L, de Wit VHW, van de Weijer T, Aarts S, Lutgens E, Schomakers BV, Elfrink HL, Zapata-Perez R, Houtkooper RH, Auwerx J, Hoeks J, Schrauwen-Hinderling VB, Phielix E, Schrauwen P. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. *Am J Clin Nutr*. 2020;112:413-426. (IF: 6,766)
54. Rigby A, Lip GYH, Weber C. Documenting Sex and Sex Differences in Animal Studies. *Thrombosis and haemostasis*. 2020;120:879-882. (IF: 4,385)
55. Sanchez-Diaz M, Nicolas-Avila JA, Cordero MD, Hidalgo A. Mitochondrial Adaptations in the Growing Heart. *Trends Endocrinol Metab*. 2020;31:308-319. (IF: 3,257)
56. Santovito D. From Beneficial to Detrimental: How Nicotine Hijacks the Autophagy Machinery. *Arterioscler Thromb Vasc Biol*. 2020;40:1955-1957. (IF: 6,604)
57. Santovito D, Egea V, Bidzhekov K, Natarelli L, Mourao A, Blanchet X, Wichapong K, Aslani M, Brunssen C, Horckmans M, Hristov M, Geerlof A, Lutgens E, Daemen M, Hackeng T, Ries C, Chavakis T, Morawietz H, Naumann R, Hundelshausen PV, Steffens S, Duchene J, Megens RTA, Sattler M, Weber C. Autophagy unleashes noncanonical microRNA functions. *Autophagy*. 2020;16:2294-2296. (IF: 9,770)
58. Santovito D, Egea V, Bidzhekov K, Natarelli L, Mourao A, Blanchet X, Wichapong K, Aslani M, Brunssen C, Horckmans M, Hristov M, Geerlof A, Lutgens E, Daemen M, Hackeng T, Ries C, Chavakis T, Morawietz H, Naumann R, von Hundelshausen P, Steffens S, Duchêne J, Megens RTA, Sattler M, Weber C. Noncanonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. *Sci Transl Med*. 2020;12 (IF: 16,304)
59. Santovito D, Marcantonio P, Mastroiacovo D, Natarelli L, Mandolini C, De Nardis V, Paganelli C, De Cesare D, Affaitati G, Giamberardino MA, Stellin L, Pinelli M, Weber C, De Blasis G, Occhiuzzi U, Bucci M, Desideri G, Cipollone F. High dose rosuvastatin increases ABCA1 transporter in human atherosclerotic plaques in a cholesterol-independent fashion. *Int J Cardiol*. 2020;299:249-253. (IF: 3,229)
60. Schilperoort M, van den Berg R, Bosmans LA, van Os BW, Dolle MET, Smits NAM, Guichelaar T, van Baarle D, Koemans L, Berbee JFP, Deboer T, Meijer JH, de Vries MR, Vreeken D, van Gils JM, Willems van Dijk K, van Kerkhof LWM, Lutgens E, Biermasz NR, Rensen PCN, Kooijman S. Disruption of circadian rhythm by alternating light-dark cycles aggravates atherosclerosis development in APOE*3-Leiden.CETP mice. *J Pineal Res*. 2020;68:e12614. (IF: 14,528)
61. Schnitzler JG, Hoogeveen RM, Ali L, Prange KHM, Waissi F, van Weeghel M, Bachmann JC, Versloot M, Borrelli MJ, Yeang C, De Kleijn DPV, Houtkooper RH, Koschinsky ML, de Winther MPJ, Groen AK, Witztum JL, Tsimikas S, Stroes ESG, Kroon J. Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. *Circ Res*. 2020;126:1346-1359. (IF: 14,467)
62. Schnitzler JG, Poels K, Stiekema LCA, Yeang C, Tsimikas S, Kroon J, Stroes ESG, Lutgens E, Seijkens TTP. Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. *Int J Cardiol*. 2020;315:81-85. (IF: 3,229)
63. Shami A, Atzler D, Bosmans LA, Winkels H, Meiler S, Lacy M, van Tiel C, Ta Megens R, Nitz K, Baardman J, Kusters P, Seijkens T, Buerger C, Janjic A, Riccardi C, Edsfieldt A, Monaco C, Daemen M, de Winther MPJ, Nilsson J, Weber C, Gerdes N, Goncalves I, Lutgens E. Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. *European heart journal* 2020:100893. (IF: 22,673)
64. Siess W, Hundelshausen PV, Lorenz R. Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors. *Platelets*. 2020;41:2938-2948. (IF: 3,378)
65. Silvestre-Roig C, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as regulators of cardiovascular inflammation. *Nat Rev Cardiol*. 2020;31:989-992. (IF: 20,260)
66. Steffens S, Van Linthout S, Sluijter J, Tocchetti G, Thum T, Madonna R. Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: Consensus Document from the joint 2019 meeting of the ESC Working Groups of Cellular Biology of the heart and Myocardial Function. *Cardiovascular research*. 2020;17:327-340. (IF: 8,168)
67. Sternkopf M, Nagy M, Baaten C, Kuijpers MJE, Tullema BME, Wirth J, Theelen W, Mastenbroek TG, Lehrke M, Winnerling B, Baerts L, Marx N, De Meester I, Doring Y, Cosemans J, Daiber A, Steven S, Jankowski J, Heemskerck JWM, Noels H. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions. *Arteriosclerosis, thrombosis, and vascular biology*. 2020;40:e65-e77. (IF: 6,604)
68. Stiekema LCA, Prange KHM, Hoogeveen RM, Verweij SL, Kroon J, Schnitzler JG, Dzobo KE, Cupido AJ, Tsimikas S, Stroes ESG, de Winther MPJ, Bahjat M. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). *European heart journal*. 2020;40:e65-e77. (IF: 22,673)
69. Thiem K, Hoeke G, Zhou E, Hijmans A, Houben T, Boels MG, Mol IM, Lutgens E, Shiri-Sverdlov R, Bussink J, Kanneganti TD, Boon MR, Stienstra R, Tack CJ, Rensen PC, Netea MG, Berbee JF, van Diepen JA. Deletion of haematopoietic Dectin-2 or CARD9 does not protect from atherosclerosis development under hyperglycaemic conditions. *Diab Vasc Dis Res*. 2020;17:1479164119892140. (IF: 2,707)
70. Tilstam PV, Soppert J, Hemmers C, Harlacher E, Doring Y, van der Vorst EPC, Schulte C, Alampour-Rajabi S, Theelen W, Asare Y, de Winther MPJ, Lawrence T, Bernhagen J, Schober A, Zernecke A, Jankowski J, Weber C, Noels H. Non-activatable mutant of inhibitor of kappa B kinase alpha (IKKalpha) exerts vascular site-specific effects on atherosclerosis in ApoE-deficient mice. *Atherosclerosis*. 2020;292:23-30. (IF: 3,919)
71. van der Vorst EPC. High-Density Lipoproteins and Apolipoprotein A1. *Subcell Biochem*. 2020;94:399-420 (IF: 0,5)
72. van der Vorst EPC, Biessen EAL, Donners M. Letter by van der Vorst et al Regarding Article, "Anti-Inflammatory Effects of HDL (High-Density Lipoprotein) in Macrophages Predominate Over Proinflammatory Effects in Atherosclerotic Plaques". *Arterioscler Thromb Vasc Biol*. 2020;40:e31-e32. (IF: 6,604)
73. van der Vorst EPC, Daissormont I, Aslani M, Seijkens T, Wijnands E, Lutgens E, Duchene J, Santovito D, Doring Y, Halvorsen B, Aukrust P, Weber C, Hopken

- UE, Biessen EAL. Interruption of the CXCL13/CXCR5 Chemokine Axis Enhances Plasma IgM Levels and Attenuates Atherosclerosis Development. *Thromb Haemost.* 2020;120:344-347. **(IF: 4,385)**
74. Weber C. The ESC Council on Basic Cardiovascular Science. *European heart journal.* 2020;41:1227-1230. **(IF: 22,673)**
75. Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2019 Editor's Choice Papers. *Thromb Haemost.* 2020;120:184-190. **(IF: 4,385)**
76. Willemsen L, de Winther MPJ. Macrophage subsets in atherosclerosis as defined by single-cell technologies. *The Journal of pathology* 2020;120:184-190. **(IF: 6,021)**
77. Zernecke A, Winkels H, Cochain C, Williams JW, Wolf D, Soehnlein O, Robbins CS, Monaco C, Park I, McNamara CA, Binder CJ, Cybulsky MI, Scipione CA, Hedrick CC, Galkina EV, Kyaw T, Ghosheh Y, Dinh HQ, Ley K. Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas. *Circulation research.* 2020;127:402-426. **(IF: 14,467)**
78. Zhang D, Ebrahim M, Adler K, Blanchet X, Jamasbi J, Megens RTA, Uhland K, Ungerer M, Munch G, Deckmyn H, Weber C, Elia N, Lorenz R, Siess W. Glycoprotein VI is not a Functional Platelet Receptor for Fibrin Formed in Plasma or Blood. *Thrombosis and haemostasis.* 2020;120:977-993. **(IF: 4,385)**